ProBioGen appoints Alfred Merz as chief executive

31 March 2025

German contract development and manufacturing specialist ProBioGen has named Alfred Merz as its new chief executive. He had been serving as chief operating officer and interim chief executive since joining the company in 2024 from Bayer (BAYN: DE).

Mr Merz brings more than 30 years of experience across major pharmaceutical companies, including Bayer and Novartis (NOVN: VX). At Bayer, he was senior vice president and head of product supply for medical devices.

ProBioGen, based in Berlin, is known for developing complex therapeutic proteins, viral vectors and vaccines, offering cell line and process development as well as GMP manufacturing. The company’s proprietary technologies, such as GlymaxX and DirectedLuck, are licensed by a range of biotech firms including Bayer, Innovent Biologics (HKG: 1801) and GeoVax.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK